Replies to post #659039 on NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

Or maybe it would give an extra incentive for Merck to acquire NWBO?

The CI realm will near $65B a year.

If Keytruda expires and DCVax+poly makes CI, if not obsolute, then diminish their realm much the next 5 years, then why not use the point in time to change horse?

[flipper44]

Merck apparently obtained some access to: https://www.selleckchem.com/products/pexidartinib-plx3397.html which is the final 🔑 to
the GBM cocktail, imho.

So, to answer your question, Merck has about three avenues to consider, imho,

1. Partner.
2. BO and/or
3. Contribute, maybe CI still has a role to play in certain situations.

[dstock07734]

If utilization of poly ICLC with DCVax-L substantially reduces the need to
include a CI in the mix

I have doubt about this statement. As a matter of fact, adding pd-1 inhibitor to the combination of DCVax-L + poly-iclc trigger antitumor immune response so intense that patients had to go through surgery and take immune-suppressive drug. Recall the patient #5 from Dr. Liau's presentation?